From the Journals

Analysis of PsA guidelines reveals much room for improvement on conflicts of interest


 

FROM ARTHRITIS CARE & RESEARCH

Nonfinancial conflicts of interest

Many authors of the ACR’s CPG and the JDA’s CPG also had NFCOI, defined objectively in this study as self-citation rate. NFCOI have been more broadly defined by the International Committee of Medical Journal Editors (ICMJE) as “conflicts, such as personal relationships or rivalries, academic competition, and intellectual beliefs”; the ICMJE recommends reporting NFCOI on its COI form.

The JDA guideline included self-citations by 78% of its authors, compared with 32% of the ACR guideline authors, but this weighed differently among the two guidelines in that only 12 of the 354 (3.4%) citations in the JDA guideline were self-cited, compared with 46 of 137 (34%) citations in the ACR guideline.

The researchers noted that while the self-citation rates between JDA and ACR authors “differed remarkably,” the impact of ACR authors on CPG recommendations was much more direct. Three-quarters of JDA authors’ self-cited articles were about observational studies, whereas 52% of the ACR authors’ self-cited articles were clinical trials, most of which were randomized, controlled studies, and these NFCOI were not disclosed in the guideline.

Half of the strong recommendations in the JDA guideline were based on low or very low quality of evidence, whereas the ACR guideline had no strong recommendations based on low or very low quality of evidence.

This study was supported by the nonprofit Medical Governance Research Institute, which receives donations from Ain Pharmacies Inc., other organizations, and private individuals. The study also received support from the Tansa (formerly known as the Waseda Chronicle), an independent nonprofit news organization dedicated to investigative journalism. Three authors reported receiving personal fees from several pharmaceutical companies for work outside of the scope of this study.

Pages

Recommended Reading

Drug survival study looks at what lasts longest in RA, axSpA, PsA, and psoriasis
Psoriatic Arthritis Resource Center
Trial gives new guidance for choosing initial PsA treatment
Psoriatic Arthritis Resource Center
Upadacitinib earns FDA approval for ankylosing spondylitis 
Psoriatic Arthritis Resource Center
‘Shielding’ status provides best indicator of COVID-19 mortality in U.K. arthritis population
Psoriatic Arthritis Resource Center
Bimekizumab calms psoriatic arthritis in phase 3 ‘BE’ trials
Psoriatic Arthritis Resource Center
Treat-to-target strategy with tapering proves effective in PsA and axSpA
Psoriatic Arthritis Resource Center
Ustekinumab becomes second biologic approved for PsA in kids
Psoriatic Arthritis Resource Center
Autoimmune disease patients’ waxing, waning response to COVID vaccination studied in-depth
Psoriatic Arthritis Resource Center
Should patients with PsA or ankylosing spondylitis with axial disease be ‘lumped’ or ‘split’?
Psoriatic Arthritis Resource Center
Psoriasis, psoriatic arthritis insurance coverage remains restrictive
Psoriatic Arthritis Resource Center